| __timestamp | Biogen Inc. | Eli Lilly and Company |
|---|---|---|
| Wednesday, January 1, 2014 | 2232342000 | 6620800000 |
| Thursday, January 1, 2015 | 2113100000 | 6533000000 |
| Friday, January 1, 2016 | 1947900000 | 6452000000 |
| Sunday, January 1, 2017 | 1935500000 | 6588100000 |
| Monday, January 1, 2018 | 2106300000 | 5975100000 |
| Tuesday, January 1, 2019 | 2374700000 | 6213800000 |
| Wednesday, January 1, 2020 | 2504500000 | 6121200000 |
| Friday, January 1, 2021 | 2674300000 | 6431600000 |
| Saturday, January 1, 2022 | 2403600000 | 6440400000 |
| Sunday, January 1, 2023 | 2549700000 | 6941200000 |
| Monday, January 1, 2024 | 2403700000 | 8593800000 |
Infusing magic into the data realm
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Eli Lilly and Company and Biogen Inc. have showcased contrasting strategies in this domain. From 2014 to 2023, Eli Lilly consistently reported higher SG&A expenses, averaging around 6.4 billion annually, compared to Biogen's 2.3 billion. However, Eli Lilly's expenses have shown a steady increase, peaking at 6.9 billion in 2023, a 5% rise from 2022. In contrast, Biogen's expenses have fluctuated, with a notable 38% increase from 2016 to 2023. This data suggests Eli Lilly's strategy might focus on expansive growth, while Biogen appears to be optimizing costs more aggressively. As these companies continue to evolve, their SG&A strategies will remain pivotal in shaping their financial futures.
Cost of Revenue Comparison: Eli Lilly and Company vs Biogen Inc.
Comparing SG&A Expenses: Eli Lilly and Company vs Neurocrine Biosciences, Inc. Trends and Insights
Selling, General, and Administrative Costs: Eli Lilly and Company vs Verona Pharma plc
Comparing SG&A Expenses: Eli Lilly and Company vs CRISPR Therapeutics AG Trends and Insights
Eli Lilly and Company vs Amicus Therapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Eli Lilly and Company vs MorphoSys AG
Eli Lilly and Company vs Supernus Pharmaceuticals, Inc.: SG&A Expense Trends
Operational Costs Compared: SG&A Analysis of Merck & Co., Inc. and Biogen Inc.
SG&A Efficiency Analysis: Comparing Novartis AG and Biogen Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Biogen Inc.
Biogen Inc. vs Ionis Pharmaceuticals, Inc.: SG&A Expense Trends
Biogen Inc. and Amneal Pharmaceuticals, Inc.: SG&A Spending Patterns Compared